High-Level Overview
Endovascular Engineering (E2) is a venture-funded medical device startup based in Menlo Park, California, developing innovative thrombectomy systems for venous thromboembolism (VTE), including pulmonary embolism (PE).[1][2][3][5] The company builds the Hēlo™ Thrombectomy System, a small-profile catheter with a self-expanding funnel design that enables large-bore clot engagement through high-speed agitation and physician-controlled aspiration, serving hospitals and clinicians treating critical vascular clot conditions.[1][4][5] It addresses limitations of existing devices by combining small-profile navigation in complex anatomies with effective single-pass clot removal, improving patient outcomes in VTE cases; the firm has raised $42M in Series B funding and advanced from preclinical to pivotal clinical trials like ENGULF, with enrollment completed in 2025.[1][2][4]
Origin Story
Founded in 2019, Endovascular Engineering emerged from expertise in vascular interventions, led by Luis Savastano as Founder and President, with Dan Rose as CEO.[2] The idea stemmed from unmet needs in mechanical thrombectomy for peripheral and venous indications, particularly VTE, where current tools struggle with clot burden in challenging anatomies.[1][2][3] Early traction included transitioning from stealth/preclinical stages to positive ENGULF feasibility results in 2024 and pivotal cohort enrollment completion for PE treatment by June 2025, alongside appointing a CFO in September 2025 to fuel growth.[2][4]
Core Differentiators
- Hēlo™ System Design: Unique self-expanding funnel ensures wide distal opening for large-bore performance, with dual-action high-speed agitation and aspiration for efficient single-pass clot removal in complex vessels.[5]
- Small-Profile Agility: Enables navigation through the heart and tortuous anatomies with a lower hemodynamic footprint than traditional large-bore systems, reducing patient risk.[1][5]
- Clinical Momentum: Positive safety/feasibility from ENGULF trial (2024) and completed pivotal enrollment (2025), positioning for commercialization.[2][4]
- Leadership Expertise: Backed by vascular specialists like Savastano, with $42M funding supporting rapid R&D advancement.[1][2][4]
Role in the Broader Tech Landscape
Endovascular Engineering rides the VTE treatment boom, driven by rising PE incidence and demand for minimally invasive catheter-based solutions over surgery or thrombolytics.[1][3][5] Timing aligns with post-pandemic clot surges and regulatory tailwinds for next-gen devices, as market forces favor agile systems reducing procedure times and complications amid aging populations.[2][4] It influences medtech by bridging small- and large-bore tech, potentially setting standards for PE/VTE care and attracting partnerships with larger firms.[1][5]
Quick Take & Future Outlook
With pivotal ENGULF data presented at VIVA 2025 and a new CFO steering commercialization, E2 is poised for FDA clearance and market entry in 2026-2027.[2] Trends like AI-guided imaging and expanded VTE indications will amplify its trajectory, evolving its role from innovator to ecosystem shaper via acquisitions or IPO. This positions Endovascular Engineering as a high-momentum player redefining vascular thrombectomy, enhancing outcomes where clots threaten lives.[1][2][5]
